Role of Anti-IgE in Severe Childhood Eczema (ADAPT)
The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema
Sponsor: Guy's and St Thomas' NHS Foundation Trust
A PHASE4 clinical study on Atopic Dermatitis and Atopic Eczema, this trial is completed. The trial is conducted by Guy's and St Thomas' NHS Foundation Trust and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Sep 2017 — Mar 2018 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE4
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guy's and St Thomas' NHS Foundation Trust
- King's College London
- National Institute for Health Research, United Kingdom
For direct contact, visit the study record on ClinicalTrials.gov .